Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant/Fosaprepitant for CINV in Colorectal Cancer (SENRI)
NCT01344304Phase 3Completed
- Sponsor
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
- Start
- Apr 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprepitant, fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group. Started Apr 2011; status: completed.
02
Drugs
aprepitantfosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01344304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01344304.